Related Experiment Video
Updated: Sep 11, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Decoding the Impact of Genetic Polymorphisms in Xenobiotic Metabolizing Enzymes and Ovarian Cancer: A Comprehensive
Harshavardhani Canchi Sistla1, Srikanth Talluri2, Sivaramakrishnan Venkatabalasubramanian3
1Cancer Genomics Laboratory, Department of Biotechnology, School of Chemical and Biotechnology, SASTRA-Deemed University, Thanjavur, India.
Abstract:
Ovarian cancer (OC), the third most common and fatal gynecological malignancy, is a heterogeneous disease characterized by genomic instability. The interaction between genetic and environmental factors, including xenobiotics, plays a crucial role in OC initiation, progression, and treatment resistance. Xenobiotic metabolism (XM) is a key process for metabolizing and detoxifying environmental carcinogens, drugs, and other xenobiotics. Variations in XM genes (XMGs), such as those encoding cytochrome P450s (CYPs), UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), N-acetyltransferases, and glutathione S-transferases (GSTs), can alter enzyme activity, thereby affecting detoxification, hormone metabolism, and clinical outcomes. Previous research has shown the effects of genetic variants on XM in OC, underscoring the importance of pharmacogenomics in tailoring personalized treatments. However, challenges persist, including individual variability, study inconsistencies, and insufficient ovarian-specific data on XM. This review provides a comprehensive overview of XM in OC. It emphasizes the importance of phase I and II enzymes in detoxification and biotransformation, and ABC transporters in drug metabolism and chemoresistance. This review provides insights into the emerging roles of CYPs, GSTs, glutathione peroxidases, myeloperoxidase, catalase, superoxide dismutase, SULTs, and UGTs, and addresses the need for further research to understand their influence on OC risk and prognosis. By addressing the gaps in ovarian-specific XM research, including their role in susceptibility and treatment response, these insights have the potential to advance targeted therapeutic strategies and overcome the challenges of chemoresistance in OC.
Related Concept Videos
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Oogenesis
Nonlinear Pharmacokinetics: Role of Transporters
Polymorphisms occurring in drug transporters can alter...
Mutagenicity and Carcinogenicity
Cancer Prevention
Some...
Single Nucleotide Polymorphisms-SNPs

